Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Retained Earnings: 2015-2024

Historic Retained Earnings for Syndax Pharmaceuticals (SNDX) over the last 10 years, with Dec 2024 value amounting to -$1.2 billion.

  • Syndax Pharmaceuticals' Retained Earnings fell 27.65% to -$1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.4 billion, marking a year-over-year decrease of 27.65%. This contributed to the annual value of -$1.2 billion for FY2024, which is 35.32% down from last year.
  • According to the latest figures from FY2024, Syndax Pharmaceuticals' Retained Earnings is -$1.2 billion, which was down 35.32% from -$902.4 million recorded in FY2023.
  • In the past 5 years, Syndax Pharmaceuticals' Retained Earnings ranged from a high of -$543.7 million in FY2021 and a low of -$1.2 billion during FY2024.
  • For the 3-year period, Syndax Pharmaceuticals' Retained Earnings averaged around -$938.9 million, with its median value being -$902.4 million (2023).
  • In the last 5 years, Syndax Pharmaceuticals' Retained Earnings climbed by 4.38% in 2021 and then tumbled by 35.32% in 2024.
  • Syndax Pharmaceuticals' Retained Earnings (Yearly) stood at -$568.6 million in 2020, then rose by 4.38% to -$543.7 million in 2021, then fell by 27.47% to -$693.0 million in 2022, then plummeted by 30.21% to -$902.4 million in 2023, then plummeted by 35.32% to -$1.2 billion in 2024.